OTN Mitoxantrone and Promacta (Eltrombopag Powder for Suspension)
Determining the interaction of OTN Mitoxantrone and Promacta (Eltrombopag Powder for Suspension) and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Eltrombopag may increase the blood levels and effects of mitoXANTRONE. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with eltrombopag may increase the plasma concentrations of drugs that are substrates of the organic anion transporting polypeptide (OATP) 1B1 and/or breast cancer resistance protein (BCRP) transporters. The mechanism is decreased clearance due to inhibition of OATP1B1-mediated hepatic uptake and BCRP-mediated intestinal and hepatobiliary efflux by eltrombopag. The interaction has been demonstrated for rosuvastatin, a known substrate of both OATP 1B1 and BCRP. In 39 healthy adult subjects given eltrombopag 75 mg once daily for 4 days prior to coadministration with a single 10 mg dose of rosuvastatin on day 5, mean rosuvastatin peak plasma concentration (Cmax) increased by 103% and systemic exposure (AUC) by 55%.
MANAGEMENT: Caution is advised during concomitant use of eltrombopag with drugs that are substrates of the OATP1B1 and/or BCRP transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever eltrombopag is added to or withdrawn from therapy.
- Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9
- Kalliokoski A, Niemi M "Impact of OATP transporters on pharmacokinetics." Br J Pharmacol 158 (2009): 693-705
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- "Product Information. Promacta (eltrombopag)." GlaxoSmithKline, Research Triangle Park, NC.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: mitoxantrone
Brand name: Novantrone
Synonyms: Mitoxantrone, MitoXANtrone
Generic Name: eltrombopag
Brand name: Promacta
Synonyms: Promacta
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- OTN Mitoxantrone-Promacta (Eltrombopag Tablets)
- OTN Mitoxantrone-Promethazine
- OTN Mitoxantrone-Promethazine and Phenylephrine
- OTN Mitoxantrone-Promethazine Hydrochloride
- OTN Mitoxantrone-Promethazine injection
- OTN Mitoxantrone-Promethazine Injection, Intravenous
- Promacta (Eltrombopag Powder for Suspension)-Otrexup
- Promacta (Eltrombopag Powder for Suspension)-Otrexup injection
- Promacta (Eltrombopag Powder for Suspension)-Outgro
- Promacta (Eltrombopag Powder for Suspension)-Ovcon 35
- Promacta (Eltrombopag Powder for Suspension)-Ovidrel
- Promacta (Eltrombopag Powder for Suspension)-Ovidrel injectable